Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2024-03-01 00:00:00 ET · period of report 2024-02-29 · accession 0001562180-24-002022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-01 | 2024-02-29 | AKBA | Hadas Nicole R. | SVP, CLO | S - Sale | $1.58 | -5,974 | 663.3K | -0.9% | -$9,439 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-29 | S | D | 5,974 | $1.58 | 663,259 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. |